Camp4 Therapeutics CORP Form 4 insider transactions

Andrew J. Schwab, a Director and 10% owner of Camp4 Therapeutics Corp, was granted 9,000 stock options with an exercise price of $1.56 per share, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Steven H. Holtzman, a Director at Camp4 Therapeutics Corp, was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of one year from the grant date or the next annual meeting.

Amir Nashat, a Director and 10% owner of Camp4 Therapeutics Corp, acquired 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Camp4 Therapeutics Corp. Director Ravi I. Thadhani was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Camp4 Therapeutics Corp director Paula Ragan was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service.

David Bumcrot, Chief Scientific Officer of Camp4 Therapeutics Corp, acquired stock options for 45,000 shares on April 1, 2025.

Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, acquired stock options for 80,000 shares on April 1, 2025.

Kelly Gold, CFO of Camp4 Therapeutics, was granted stock options for 80,000 shares on April 1, 2025, according to a Form 4 filing.

Josh Mandel-Brehm, CEO of Camp4 Therapeutics, reports the acquisition of stock options.

Director Douglas E. Williams reports receiving a stock option grant from Camp4 Therapeutics.

Director Murray Stewart reports acquisition of stock options in Camp4 Therapeutics, signaling potential confidence in the company's future.

Polaris Management Co. VII, L.L.C. amends its Form 4 filing to include Brian Chee as an additional reporting person after the automatic conversion of preferred stock to common stock following Camp4 Therapeutics' IPO.

Northpond Ventures and related entities report the conversion of preferred stock to common stock in Camp4 Therapeutics Corp following the company's initial public offering.

AH Equity Partners and related entities, including Marc Andreessen and Benjamin Horowitz, report changes in beneficial ownership of Camp4 Therapeutics Corp. common stock following the conversion of preferred stock in connection with the company's initial public offering.

Enavate Sciences GP, LLC and Everest Aggregator, LP report transactions involving Camp4 Therapeutics Corp stock, including conversion of preferred stock and open market purchases.

Polaris Partners and related entities report the conversion of preferred stock to common stock and the purchase of additional common stock following Camp4 Therapeutics' initial public offering.

5AM Partners VI, LLC and related entities report changes in beneficial ownership of Camp4 Therapeutics Corp. stock due to the conversion of preferred stock into common stock upon the company's IPO.

Amir Nashat, a director and affiliated with Polaris Partners, reports changes in beneficial ownership of Camp4 Therapeutics Corp stock following the company's initial public offering.

Director Andrew Schwab reports the conversion of preferred stock to common stock and a purchase of common stock following Camp4 Therapeutics' initial public offering.

Director Steven H. Holtzman converted Series A Prime Preferred Stock to Common Stock in Camp4 Therapeutics following the company's initial public offering.

Director Richard Young reports the automatic conversion of Series A Prime Convertible Preferred Stock into Common Stock following Camp4 Therapeutics' initial public offering.

CEO Josh Mandel-Brehm converted Series B Preferred Stock to Common Stock following Camp4 Therapeutics' initial public offering.